Diabetes pill may cut lung cancer risk in COPD patients, study suggests
NCT ID NCT07332156
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at medical records of over 21,000 adults with type 2 diabetes and COPD to see if a diabetes drug called SGLT2 inhibitor lowers the chance of getting lung cancer compared to an older drug, sulfonylurea. Researchers did not give anyone new medicine; they just analyzed existing health data. The goal is to find out if SGLT2 inhibitors might have an extra benefit beyond controlling blood sugar.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SGLT2 inhibitors
- What this could lead to
- If SGLT2 inhibitors are linked to fewer lung cancer cases, this could point toward a new way to lower cancer risk in high-risk patients.
- What could go wrong
- This is an observational study, not a controlled trial, so it can only show a link, not prove cause and effect. Other factors could explain any differences seen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Could remote rehab keep COPD patients out of the hospital?
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Which lung biopsy method is safer and more accurate?